0001209191-23-038827.txt : 20230621
0001209191-23-038827.hdr.sgml : 20230621
20230621170037
ACCESSION NUMBER: 0001209191-23-038827
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230616
FILED AS OF DATE: 20230621
DATE AS OF CHANGE: 20230621
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WIERENGA WENDALL
CENTRAL INDEX KEY: 0001235945
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38583
FILM NUMBER: 231030657
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
STREET 2: C/O NEUROCRINE BIOSCIENCES
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER NAME:
FORMER CONFORMED NAME: WIERENGA WENDALL D
DATE OF NAME CHANGE: 20030527
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658247
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263744114
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-450-6464
MAIL ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-16
0
0001658247
Crinetics Pharmaceuticals, Inc.
CRNX
0001235945
WIERENGA WENDALL
C/O CRINETICS PHARMACEUTICALS, INC.
10222 BARNES CANYON ROAD, BLDG 2
SAN DIEGO
CA
92121
1
0
0
0
0
Common Stock
2023-06-16
4
A
0
6000
0.00
A
105846
D
Stock Option (right to buy)
20.32
2023-06-16
4
A
0
17500
0.00
A
2033-06-15
Common Stock
17500
17500
D
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
The stock option shall vest and become exercisable on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
/s/ Marc Wilson
2023-06-21